Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Cancer Pain 1

Interventions

Morphine 6Analgesia 6nabiximols 3Pregabalin 3Oxycodone 3Fentanyl 3ziconotide 2Surveys and Questionnaires 2Saline Solution 2Radiofrequency Ablation 2Methadone 2Lidocaine 2Ketamine 2Ibandronic Acid 2Gemcitabine 2Duloxetine Hydrochloride 2Docetaxel 2Botulinum Toxins, Type A 2trimebutine 3-thiocarbamoylbenzenesulfonate 1tanezumab 1tandutinib 1siltuximab 1resiniferatoxin 1incobotulinumtoxinA 1imisopasem manganese 1fulranumab 1erenumab 1cyclobenzaprine 1caffeine, sodium benzoate drug combination 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pain × fulranumab × Clear all
NCT00929188 2016-01-22

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Janssen Research & Development, LLC

Phase 2 Completed
100 enrolled

Cancer Pain, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡